We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bruker Daltonics Launches Drug and Small Molecule MALDI Imaging Solution for the apex®-ultra FTMS

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Bruker Daltonics Launches Drug and Small Molecule MALDI Imaging Solution for the apex®-ultra FTMS"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

At Pittcon 2008, Bruker Daltonics has announces the addition to its molecular imaging portfolio – the high performance apex-ultra® FTMS equipped with Bruker’s proprietary SmartBeam™ laser technology.

The high sensitivity SmartBeam™ MALDI ion funnel source coupled with ultra-high mass resolution FTMS make the apex-ultra® ideally suited for tissue imaging of small molecules, including drugs from animals dosed at therapeutic levels, e.g. at 5 mg/kg and lower. This new imaging solution promises to advance areas such as drug development and delivery, clinical and pathology research, as well as other areas of biological research such as lipidomics.

The MALDI source of the apex-ultra® is the Apollo II dual ESI/MALDI source based on the patented ion funnel technology, which provides the combination of high sensitivity between ESI and MALDI.

The addition of the SmartBeam™ laser technology, developed initially for the Bruker Flex line of TOF/TOFs, creates a MALDI source that provides the necessary 200 Hz repetition rate laser and less than 40 micron spot size. SmartBeam™ is also compatible with the full range of matrix choices for MALDI.

The performance of the apex-ultra® in the low-m/z region (150 – 2,000 m/z) is exceptional and does not suffer from complications of matrix background. With mass resolution greater than 900,000 (at 7 Tesla), the cluttered spectra produced in MALDI imaging of tissue samples are readily dissected, allowing for the first time MALDI-MS imaging of small molecules without the requirement to go to tandem mass spectrometry (MS/MS or TOF/TOF) for chemical background suppression.

Another key attribute of the apex-ultra® for small molecule MALDI imaging arises from its hybrid geometry: its Qq-interface allows Continuous Accumulation of Selected Ions (CASI™), which can enhance the dynamic range by enhancing low abundant signals produced in MALDI Imaging by an order of magnitude. This is essential for localizing even lower level therapeutic drug levels and drug metabolites in tissues.

Managing the imaging analysis results is straightforward with flexImaging™ solution that guides the researcher through the analytical workflow from data acquisition to data evaluation and image viewing.

Finally, the new MALDI-imaging solution for the apex-ultra® is fully compatible with the other Bruker molecular imaging tools for a unique, complete MALDI-imaging solution.